



Study Participants

Russell H. Samson, M.D.	Vascular and Surgery Associates	Sarasota, Florida
David P. Showalter, M.D.	Vascular and Surgery Associates	Sarasota, Florida
Douglas A. Dorsay, M.D.	Vascular and Surgery Associates	Sarasota, Florida
Jonathan P. Yunis, M.D.	Vascular and Surgery Associates	Sarasota, Florida

Results of this study have been included in a paper submitted for publication.

Mission Statement:

PERPOS (Peripheral Retrospective PTFE Outcome Study) is designed to demonstrate the clinical safety and efficacy of Atrium's Advanta[™] VS PTFE vascular grafts when used in lower limb vascular reconstruction compared to other commercially available PTFE grafts.



ATRIUM




ATRIUM

ATRIUM MEDICAL CORPORATION
5 Wentworth Drive
Hudson, New Hampshire 03051 U.S.A.
☎ 603-880-1433 📠 603-880-6718

ATRIUM EUROPE B.V.
Rendementsweg 20B
3641 SL Mijdrecht, The Netherlands
☎ +31-297-230-420 📠 +31-297-282-653

ATRIUM AUSTRALIA-PACIFIC RIM PTY. LTD.
Level 6, 579 Harris Street
Ultimo NSW 2007 Australia
☎ +61-2-8272-3100 📠 +61-2-8272-3199



PERPOS

PERPOS is a retrospective study designed to demonstrate the clinical safety and efficacy of Atrium's Advanta[™] VS PTFE vascular grafts when used in lower limb vascular reconstruction compared to other commercially available PTFE grafts.



ATRIUM

PERPOS
Peripheral
Retrospective
PTFE Outcome Study

PERPOS was conducted by Russell H. Samson, M.D. and associates, of Sarasota, Florida to assess the continued effective use of PTFE grafts for femoropopliteal bypass. This study compares commercially available PTFE grafts from Atrium and W.L. Gore. This single center study represents more than 250 patients. All results reported are for femoropopliteal bypass above the knee (AK) and were performed by a 4 surgeon community vascular practice using similar operative techniques. Gore-Tex® grafts were used exclusively from 1988 to 1994. Beginning in 1995, both Atrium Advanta™ VS PTFE vascular grafts and Gore-Tex® grafts were used indiscriminately based on random surgeon preference.

Primary Patency*


Life-Table Data

Month	Atrium (n=70)	Gore-Tex® (n=187)
1	100.0%	97.8%
6	87.5%	91.0%
12	82.6%	82.4%
18	82.6%	77.8%
24	78.1%	73.3%
36	71.0%	62.7%

p-value = .7315

Primary Patency*

36 Month Above the Knee Femoropopliteal Bypass Life-Table Results



Secondary Patency*


Life-Table Data

Month	Atrium (n=70)	Gore-Tex® (n=187)
1	100.0%	98.9%
6	89.2%	93.9%
12	86.7%	86.9%
18	86.7%	82.1%
24	86.7%	81.0%
36	79.5%	73.7%

p-value = .8054

Secondary Patency*

36 Month Above the Knee Femoropopliteal Bypass Life-Table Results




Life-Table Results


The 3 year secondary patency results of the PERPOS study indicate that the Atrium Advanta™ VS PTFE vascular graft is safe and effective at all time points of the study period, when compared to Gore-Tex® grafts in the same (AK) femoropopliteal position. At 12 months, the secondary patency rate for Atrium was 86.7% and 86.9% for Gore-Tex®.

For 24 months, Atrium reported 86.7% patency while Gore-Tex® reported 81.0%. At 36 months, secondary patency for Atrium is 79.5% with Gore-Tex® at 73.7%.


Secondary Patency* at 12 months



Secondary Patency* at 24 months



Secondary Patency* at 36 months



* Reference Robert B. Rutherford, MD, J. Dennis Baker, MD, Calvin Ernst, MD, K. Wayne Johnston, MD, John M. Porter, MD, Sam Ahn, MD, and Darrell N. Jones, PhD. Recommended standards for reports dealing with lower extremity ischemia: Revised version. (J Vasc Surg 1997;26:517-38.)

